BOULDER, CO / ACCESSWIRE / January 25, 2023 / Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA), a global healthcare leader developing plus producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral and nasal care, and wound care, today announced that Microcyn ® Rx items have received a Distribution plus Pricing Agreement (DAPA) for distribution by the Protection Logistics Agency (DLA).

The DAPA enables our partner, EMC Pharma, to enter into distribution agreements for Microcyn® Rx products with federal customers. The particular U. S. government is the world’s largest purchaser of good and services. Approximately half of EMC Pharma’s customers are U. H. government entities, including VA hospitals, the Department associated with Defense, the particular Federal Bureau of Prisons, as well as state and local prison systems. EMC Pharma is the 100% minority-owned and a certified Minority Business Enterprise (MBE).

The DAPA approval process was a coordinated effort by Sonoma and EMC Pharma and resulted in obtaining DAPA # SP0200-22-H-0034 with regard to Sonoma’s Microcyn Rx items including wound care, prescription dermatology products, Celacyn ® plus Levicyn ® , and prescription eye care Acuicyn ® .

“This is a major step that will allow us to sell Microcyn technologies products into the federal supply chain. We have already seen interest from federal networks for these products and are excited to use our experience working with federal customers to distribute Microcyn, ” said Eric Bailey, CEO and President of ELECTRONIC COUNTER MEASURE (ECM) Pharma.

“We are proud to work with partners like EMC who have built the substantial business selling in to the numerous departments of the U. T. government, and we are usually excited to introduce the particular efficacy plus safety of our Microcyn technology items to these types of federal clients, ” said Amy Trombly, CEO associated with Sonoma. She continued, “sales to the U. S government through ELECTRONIC COUNTER MEASURE (ECM) Pharma represent a new distribution channel regarding Sonoma increasing the range of customers and regions we sell in order to. ”

About EMC Pharma, LLC

ELECTRONIC COUNTER MEASURE (ECM) Pharma, LLC is a specialty pharmaceutical company committed to bringing innovative, cost effective medications to its stakeholders. EMC Pharma is the pharmaceutical manufacturing and submission company focused on sales, marketing plus distribution associated with prescription pharmaceuticals within a full spectrum of therapeutic areas and dosage forms. EMC Pharma leverages its global network associated with developers and manufacturing companions to create an expanding portfolio of pharmaceutic products commercialized for the US market. Further information about EMC Pharma can be found at .

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a global healthcare leader intended for developing plus producing stable hypochlorous acidity (HOCl) products for a broad range of applications, which includes wound treatment, eye care, nasal treatment, oral care, and dermatological conditions. The company’s items reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe plus effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to possess impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itch plus pain, kills pathogens and breaks down biofilm, does not sting or irritate skin, plus oxygenates the cells in the area treated, assisting the body in its natural healing process. The company’s products are sold either directly or via partners in 55 countries worldwide and the particular company actively seeks new distribution companions. The company’s principal office will be in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are usually headquartered in Roermond, Netherlands. More information can be found at . For partnership opportunities, please contact [email protected] com .

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning associated with the “safe harbor” provisions of the particular Private Securities Litigation Reform Act of 1995, including statements regarding the commercial and technology progress plus future financial performance associated with Sonoma Pharmaceutical drugs, Inc. and its subsidiaries (the “company”). These forward-looking statements are identified by the use of words such as “continue, ” “develop” and “expand, ” among others. Forward-looking statements in this particular pr release are subject to certain risks and uncertainties inherent in the company’s company that could cause actual results to vary, including this kind of risks that regulatory clinical and guideline developments may change, scientific data might not be sufficient in order to meet regulatory standards or even receipt associated with required regulating clearances or approvals, medical results may not be replicated within actual patient settings, protection offered simply by the company’s patents and patent applications may be challenged, invalidated or even circumvented by its competitors, the available market for that company’s products will not be as large as expected, the carrier’s products will not become able to penetrate one or more targeted markets, revenues will not be sufficient to meet the particular company’s cash needs, fund further development, as well as questions relative to the COVID-19 pandemic and economic advancement, varying product formulations plus a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed through time in order to time within the company’s filings with the Securities plus Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals™, Microcyn ® , Celacyn ® , Levicyn ® , and Acuicyn ® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Incorporation. All other art logos and service marks are usually the property of their respective owners.

Media plus Investor Contact:

Sonoma Drugs, Inc.
ir[email protected] com

SOURCE: Sonoma Pharmaceuticals, Inc.

View source version on accesswire. com:

Leave a Reply

Your email address will not be published. Required fields are marked *